Navigation Links
BD Announces Acquisition of Cytopeia
Date:5/13/2008

Expands Portfolio of Advanced Flow Cytometry Platforms

FRANKLIN LAKES, N.J., May 13 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it has acquired all of the outstanding stock of Cytopeia, a privately held Washington corporation based in Seattle that develops and markets advanced flow cytometry cell sorting instruments.

Financial terms of this transaction were not disclosed. The acquisition is not expected to have a material impact on BD's fiscal year 2008 earnings.

"This strategic acquisition brings new technologies and capabilities that will enhance BD's ability to address growing customer needs in advanced applications, such as cell therapy research," said William A. Kozy, BD Executive Vice President. "This transaction reflects our commitment to bringing innovative tools to life scientists and will allow us to rapidly enter emerging areas of cell-based research."

Cytopeia's Influx(TM) cell sorter offers BD an open, configurable cell sorting platform that can be fully optimized for researchers' unique application-specific requirements. This high level of choice and control is particularly important for life science research on the leading edge of biomedical discovery. The Influx cell sorter is suited for a range of applications including cell therapy research, stem cell research, drug discovery and development, as well as marine biology. It complements the BD FACSAria(TM) II system -- the platform of choice in research labs around the world for a broad range of immunology cell sorting and multi-color applications.

Through the acquisition, BD gains the scientific leadership and insights of Dr. Ger van den Engh, a renowned innovator in flow cytometry. Dr. van den Engh will join BD Biosciences, a segment of BD, as Vice President, Advanced Cytometry. In this role, he will manage continuing research and technology development activities in Seattle.

"In addition to access to BD Biosciences' unparalleled portfolio of cellular research tools, Cytopeia's customers will benefit from our high- quality manufacturing and global customer support capabilities," Kozy said.

BD Biosciences is a pioneer and leader in the field of flow cytometry for cellular analysis. BD manufactured the first BD FACS(TM) (fluorescence- activated cell sorting) system in 1973. Today, BD Biosciences offers broad portfolios of research and clinical flow cytometry platforms and reagents designed for cellular characterization and sorting, as well as tools to aid in drug discovery and the growth of living cells and tissue.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit http://www.bd.com.

This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statement to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.


'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Chindex International Announces Shelf Registration, Related Strategy and Guidance
2. Amicus Therapeutics Announces First Quarter 2008 Financial Results
3. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008
4. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
5. China Sky One Medical, Inc. Announces Record First Quarter 2008 Results
6. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
7. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
8. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
9. Aton Pharma Announces Distribution Partnership in Brazil
10. China Medicine Announces Solid First Quarter 2008 Results
11. Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its unaudited financial results for the third quarter and ... 31, 2016. Third Quarter of Fiscal 2017 ... of fiscal 2017 increased by 18.6% to RMB200.9 million ...
(Date:2/23/2017)... and NEW YORK , ... Lumeon , a leading digital health company, ... a provider of telemedicine and remote patient monitoring, ... for telemedicine reimbursements.  DN Telehealth ... patients, in real-time, extending consultations beyond a physical ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... ... 2017 , ... David Nolte, PhD accepted Purdue University’s 2016 ... Research Park of West Lafayette, Indiana. , The top commercialization award is ... success with, commercializing discoveries from Purdue research. “This award is truly an honor. ...
Breaking Biology Technology:
(Date:2/6/2017)... 6, 2017 According to Acuity Market ... border authorities to continue to embrace biometric and ... 2143 Automated Border Control (ABC) eGates and 1436 ... more than 163 ports of entry across the ... achieving a combined CAGR of 37%. APC Kiosks ...
(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
(Date:1/30/2017)... 2017   Invitae Corporation (NYSE: ... companies, today announced that it will report its fourth ... guidance on Monday, February 13, 2017, and Invitae,s management ... 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... review financial results, guidance, and recent developments and will ...
Breaking Biology News(10 mins):